AN2 Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
Contents
Other Information
Item 5. Other Information.
During the fiscal quarter ended March 31, 2024, the following member of our Board of Directors adopted a “Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408(a), as follows:
On January 24, 2024, Joseph Zakrzewski adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of up to 260,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Theduration of the trading arrangement is until December 31, 2024.
None of our other directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended)adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.